ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CEL Celadon Pharmaceuticals Plc

61.00
1.50 (2.52%)
Last Updated: 14:00:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.52% 61.00 57.00 65.00 61.00 59.50 59.50 3,683 14:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 149k -7.14M -0.1082 -5.50 39.26M

Mytrah Energy Ltd Commissioning of 16.8 MW Wind Energy Project (3147A)

28/09/2015 7:01am

UK Regulatory


Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Celadon Pharmaceuticals Charts.

TIDMMYT

RNS Number : 3147A

Mytrah Energy Ltd

28 September 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

28 September 2015

Mytrah Energy Limited

('Mytrah' or 'the Company')

Commissioning of 16.8 MW wind energy project in Rajasthan, India

Mytrah, the India-based renewable focused Independent Power Producer, is pleased to announce the commissioning of the first phase of its wind energy project in Bhesada, Rajasthan ahead of plan.

The 50 MW project will ultimately see the installation of 24 Suzlon wind turbine generators of 2.1 MW each. Phase one, which commences production today, includes an initial 16.8 MW, with the remainder following ahead of the 2016 wind season.

Including this new capacity, Mytrah's wind power portfolio has increased to 560 MW across six Indian states - Rajasthan, Gujarat, Maharashtra, Andhra Pradesh, Karnataka and Tamil Nadu. The project is the first of 200 MW of new wind power capacity expected to be added before the 2016 wind season.

Commenting on the latest developments, Ravi Kailas, Chairman and CEO, said: "The commissioning of this wind energy project, well ahead of our original plan, is a strong demonstration of our execution capability. It is the first part of 200 MW of additional capacity which we have planned for the 2016 wind season.

"The demand for renewable energy in India continues to increase, with a Government target of 170 GW by 2022. This supportive environment, combined with Mytrah's extensive project pipeline and financial strength positions the company for continued growth."

For further information please visit www.mytrah.com or contact:

 
 Mytrah Energy Limited                  +44 (0)20 3402 
  Ravi Kailas / Bob Smith                5790 
 Investec Bank plc                      +44 (0)20 7597 
  Chris Sim / Jeremy Ellis               5970 
 
 Mirabaud Securities LLP                  +44 (0)20 7878 
  Peter Krens / Rory Scott                3360 
 
 Yellow Jersey PR Limited                 +44 (0)77 4778 
  Charles Goodwin / Dominic Barretto      8221 
 

About Mytrah Energy Ltd. Mytrah Energy Ltd. (AIM: MYT), the pioneer and one of the largest Independent Power Producers ('IPP') in renewable energy, in India, with 560 MW of wind power generation across 11 projects and 6 States. The Company has 172 wind masts installed across multiple states in India, providing a rich source of information from which to select its future projects. Mytrah currently has an active development pipeline of about 3500 MW of wind and 500 MW of solar.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUBOKRVSAKURR

(END) Dow Jones Newswires

September 28, 2015 02:01 ET (06:01 GMT)

1 Year Celadon Pharmaceuticals Chart

1 Year Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock